Homepage
Author:
Kyverna Therapeutics, Inc.
Posted Date:
June 3, 2026
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Kyverna Therapeutics, Inc.
June 3, 2026
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Kyverna Therapeutics, Inc.
May 22, 2026
Kyverna Therapeutics to Present at Upcoming Investor Conferences
Kyverna Therapeutics, Inc.
May 21, 2026
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
Kyverna Therapeutics, Inc.
May 21, 2026
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
Kyverna Therapeutics, Inc.
May 4, 2026
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Kyverna Therapeutics, Inc.
April 21, 2026
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
Kyverna Therapeutics, Inc.
April 20, 2026
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
Kyverna Therapeutics, Inc.
April 9, 2026
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
Kyverna Therapeutics, Inc.
March 5, 2026
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
Kyverna Therapeutics, Inc.
March 3, 2026
1
2
Next
